Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: An AIDS Malignancy Consortium Study (AMC-A03) Journal Article


Authors: Atkinson, T. M.; Palefsky, J.; Li, Y.; Webb, A.; Berry, J. M.; Goldstone, S.; Levine, R.; Wilkin, T. J.; Bucher, G.; Cella, D.; Burkhalter, J. E.; on behalf of the ANCHOR HRQoL Implementation Group
Article Title: Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: An AIDS Malignancy Consortium Study (AMC-A03)
Abstract: Purpose: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test–retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). Methods: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7–10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item. Results: Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach’s α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). Conclusions: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7–10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial. © 2019, Springer Nature Switzerland AG.
Keywords: neoplasms; health-related quality of life; patient-reported outcomes; anchor trial; clinical outcome assessments
Journal Title: Quality of Life Research
Volume: 28
Issue: 5
ISSN: 0962-9343
Publisher: Springer  
Date Published: 2019-05-01
Start Page: 1265
End Page: 1269
Language: English
DOI: 10.1007/s11136-018-2089-8
PROVIDER: scopus
PMCID: PMC6472969
PUBMED: 30617704
DOI/URL:
Notes: Article -- Export Date: 1 May 2019 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Yuelin Li
    157 Li
  2. Andrew R Webb
    3 Webb